Professor Proposes FDA Regulatory Overhaul to Lower Drug Costs

The proposal, titled "Request to Establish a Unified Reference-Anchored Equivalence Framework," argues that once patent and exclusivity protections expire, manufacturers should not be forced to repeat clinical trials that offer no new scientific insight. Niazi contends that if a product's clinically relevant characteristics can be reliably measured, regulators should shift toward an approach based on "reference-anchored equivalence." This model would rely on rigorous analytical and functional comparisons rather than mandating redundant efficacy studies for every subsequent competitor.

Niazi emphasizes that his goal is not to lower safety standards, but to make them more discriminating by focusing on residual scientific uncertainty rather than historical regulatory categories. Under this system, the burden of proof for follow-on manufacturers would be tailored to the specific product, ensuring that any new risks introduced by a manufacturing process are independently assessed. The petition explicitly respects existing patent rights and statutory protections, aiming only to clarify the regulatory path once those legal barriers to competition are removed.

If adopted, this framework could have significant global implications. Because FDA standards often dictate international regulatory expectations, a more efficient approval process for advanced therapies could lower market entry barriers for manufacturers in lower-cost regions. While the proposal does not guarantee lower prices, Niazi suggests that reducing development costs is a vital step toward making life-saving treatments, such as monoclonal antibodies and vaccines, accessible to a broader portion of the global population.